Editas Medicine, Inc.
Close on Oct 19, 2026
- Market cap
- $288.69M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | After market close | $11.90M | $-0.15 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 9, 2026 | Before market open | $24.70M | $-0.06 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | Before market open | $7.50M | $-0.28 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | After market close | $3.60M | $-0.63 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 12, 2025 | After market close | $4.70M | $-0.92 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 5, 2025 | After market close | $30.60M | $0.55 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 4, 2024 | Before market open | $100.00K | $-0.75 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | Before market open | $500.00K | $-0.82 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 28, 2024 | Before market open | – | – | – |
Press releases
Announcements Editas Medicine filed with the SEC
Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia
Regulation FD disclosure · Other events · EX-99 to Form 8-K
Editas Medicine Announces Second Quarter 2026 Results and Business Updates
Results of operations · Executive or director change · EX-99 to Form 8-K
Editas Medicine Announces Pricing of Up to
Material agreement · Other events · EX-99.1 to Form 8-K
Editas Medicine Presents EDIT-401 Preclinical
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
Regulation FD disclosure · Other events · EX-99 to Form 8-K
Editas Medicine Announces First Quarter 2026 Results and Business Updates
Results of operations · EX-99 to Form 8-K
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference
Regulation FD disclosure · Other events · EX-99 to Form 8-K
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates
Results of operations · EX-99 to Form 8-K
Editas Medicine Announces Third Quarter 2025 Results and Business Updates
Results of operations · EX-99 to Form 8-K
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32 nd Annual Congress
Regulation FD disclosure · Other events · EX-99 to Form 8-K
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
Regulation FD disclosure · Other events · EX-99 to Form 8-K
Editas Medicine Announces Second Quarter 2025 Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Editas Medicine Announces First Quarter 2025 Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years
Exit or restructuring costs · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Editas Medicine Announces Third Quarter 2024 Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept, and Strategic Update
Results of operations · Regulation FD disclosure · EX-99 to Form 8-K
Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
Material agreement · New financial obligation · Regulation FD disclosure · EX-99 to Form 8-K
Editas Medicine Announces Second Quarter 2024 Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Editas Medicine Announces First Quarter 2024 Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Editas Medicine Announces Third Quarter 2023 Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Editas Medicine Announces Second Quarter 2023 Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Editas Medicine Announces Offering of Common Stock
Material agreement · Other events · EX-99.1 to Form 8-K
Editas Medicine Announces Pricing of Offering of Common Stock
Material agreement · Other events · EX-99.2 to Form 8-K
Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Editas Medicine Announces First Quarter 2023 Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and
Results of operations · EX-99.1 to Form 8-K
Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial
Other events · EX-99.1 to Form 8-K
Editas Medicine Announces Third Quarter 2022 Results and Business Updates
Results of operations · EX-99.1 to Form 8-K